Merck (MRK) Cyclically Adjusted FCF per Share: $4.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRK Merck & Co Inc MRK
72 GF Score
Price $120.62
GF Value $118.65
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted FCF per Share?

Merck MRK -2.75% 72 Cyclically Adjusted FCF per Share is $4.63 as of Mar. 2026. GuruFocus rates MRK with a GF Score™ of 72/100 and a GF Value™ of $118.65 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merck's adjusted free cash flow per share for the three months ended in Mar. 2026 was $1.184. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $4.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Merck was 15.30% per year. The lowest was -3.70% per year. And the median was 5.30% per year.

As of today (2026-07-14), Merck's current stock price is $120.62. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $4.63. Merck's Cyclically Adjusted Price-to-FCF of today is 26.05.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.03.


Merck  (NYSE:MRK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=120.62/4.63
=26.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.03.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merck Cyclically Adjusted FCF per Share Related Terms


Merck Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted FCF per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.37 3.83 3.87 4.45 4.52

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.45 4.48 4.64 4.52 4.63

MRK vs AMGN, ABBV, GILD: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.


MRK
72GF Score
Merck & Co Inc MRK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.184/330.2130*330.2130
=1.184

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.439 241.018 0.601
201609 0.920 241.428 1.258
201612 1.110 241.432 1.518
201703 -0.019 243.801 -0.026
201706 1.063 244.955 1.433
201709 -0.591 246.819 -0.791
201712 1.210 246.524 1.621
201803 0.260 249.554 0.344
201806 1.038 251.989 1.360
201809 0.799 252.439 1.045
201812 1.011 251.233 1.329
201903 0.285 254.202 0.370
201906 0.889 256.143 1.146
201909 1.270 256.759 1.633
201912 1.470 256.974 1.889
202003 -0.110 258.115 -0.141
202006 1.104 257.797 1.414
202009 0.287 260.280 0.364
202012 1.013 260.474 1.284
202103 0.279 264.877 0.348
202106 0.592 271.696 0.720
202109 1.429 274.310 1.720
202112 1.508 278.802 1.786
202203 1.489 287.504 1.710
202206 1.249 296.311 1.392
202209 1.761 296.808 1.959
202212 1.288 296.797 1.433
202303 0.130 301.836 0.142
202306 1.079 305.109 1.168
202309 2.677 307.789 2.872
202312 -0.292 306.746 -0.314
202403 0.876 312.332 0.926
202406 1.905 314.175 2.002
202409 3.348 315.301 3.506
202412 0.991 315.605 1.037
202503 0.463 319.799 0.478
202506 1.006 322.561 1.030
202509 2.736 324.800 2.782
202512 0.734 324.054 0.748
202603 1.184 330.213 1.184

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $4.63 mean?
Merck (MRK) has a Cyclically Adjusted FCF per Share of $4.63 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted FCF per Share too high?
Merck's current Cyclically Adjusted FCF per Share is $4.63. Overall, Merck has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted FCF per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted FCF per Share of $4.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted FCF per Share is $4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MRK) is currently considered Fairly Valued. The stock's GF Value™ is $118.65, compared to a current price of $120.62 — trading 1.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $4.63. Merck's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Merck (MRK), the current Cyclically Adjusted FCF per Share is $4.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of $120.62 is trading 1.7% above its estimated GF Value™ of $118.65. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for MRK:

  • Cyclically Adjusted FCF per Share: $4.63
  • GF Value™: $118.65 vs. price of $120.62 (1.7% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for MRK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$120.62
Price
$118.65
GF Value